ASCO Annual Meeting: Gastrointestinal Cancer | Conference

Richard D. Kim, MD, Discusses the Evolving Role of Combination Therapies in HCC
July 16, 2021

CancerNetwork® sat down with Richard D. Kim, MD, of the Moffitt Cancer Center at the 2021 ASCO Annual Meeting to talk about the many ways oncologists can approach treating hepatocellular carcinoma with combination regimens.

Tanios S. Bekaii-Saab, MD, Discusses Key Findings From a Genomic and Immune Profiling Study in Intrahepatic Cholangiocarcinoma
July 12, 2021

At ASCO 2021, Tanios S. Bekaii-Saab, MD, talked about some of his research in patients with IDH1/2–positive cholangiocarcinoma presented at the meeting.

Tanios S. Bekaii-Saab, MD, on Recent Updates in GI Malignancies at ASCO 2021
July 02, 2021

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, to discuss recent updates in the treatment of gastrointestinal malignancies.

Tanios S. Bekaii-Saab, MD, on Genomic Drivers in Cholangiocarcinoma at ASCO 2021
June 26, 2021

At the 2021 American Society of Clinical Oncology Annual Meeting, CancerNetwork® spoke with Tanios S. Bekaii-Saab, MD, about genomic drivers in cholangiocarcinoma.

Frontline Regorafenib Plus Pembrolizumab Reveals Antitumor Activity in HCC
June 10, 2021

Data from a phase 1b trial of the combination of regorafenib plus pembrolizumab in patients with advanced hepatocellular carcinoma display safety and early efficacy.

Toripalimab and HAIC Plus Lenvatinib Produced Durable Responses in Advanced HCC
June 09, 2021

Adding toripalimab and hepatic arterial infusion chemotherapy to lenvatinib yielded robust, durable responses for patients with advanced hepatocellular carcinoma.

Liposomal Irinotecan Plus 5-FU/LV Improves Survival Outcomes in Biliary Tract Cancer
June 06, 2021

Liposomal irinotecan (Onivyde) plus 5-fluorouracil/leucovorin (5-FU/LV) mproved progression-free survival (PFS) and overall survival (OS) in patients with metastatic biliary tract cancer whose disease had progressed after frontline gemcitabine/cisplatin.

Upfront Camrelizumab Plus Chemotherapy Improves Survival in ESCC
June 06, 2021

Overall survival and progression-free survival was improved with frontline camrelizumab plus chemotherapy in patients with advanced or metastatic esophageal squamous cell carcinoma.

Nivolumab Combinations Superior to Chemotherapy Alone for Metastatic Esophageal Cancer
June 03, 2021

Survival outcomes improved when nivolumab was added to either ipilimumab or chemotherapy versus chemotherapy alone in advanced/metastatic esophageal squamous cell carcinoma

Scott Kopetz, MD, PhD, FACP, Discusses Next Steps for GI Oncology
January 28, 2020

The professor from MD Anderson Cancer Center spoke about the exploration of different concepts for the treatment of gastrointestinal cancers.